Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer

Clin Genitourin Cancer. 2007 Jun;5(5):347-50. doi: 10.3816/CGC.2007.n.017.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Intramural

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD / immunology*
  • Antigens, Differentiation / immunology*
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy*
  • CTLA-4 Antigen
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Genetic Vectors / therapeutic use
  • Humans
  • Male
  • Neoplasms, Hormone-Dependent / immunology
  • Neoplasms, Hormone-Dependent / therapy*
  • Prostate-Specific Antigen / genetics
  • Prostate-Specific Antigen / immunology*
  • Prostate-Specific Antigen / therapeutic use
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Cancer Vaccines
  • Prostate-Specific Antigen